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Background. Multi-drug resistant falciparum malaria is an important health problem in the Peruvian Amazon region. We
carried out a randomised open label clinical trial comparing mefloquine-artesunate, the current first line treatment in this
region, with dihydroartemisinin-piperaquine. Methods and Findings. Between July 2003 and July 2005, 522 patients with P.
falciparum uncomplicated malaria were recruited, randomized (260 with mefloquine-artesunate and 262 with dihydroarte-
misinin-piperaquine), treated and followed up for 63 days. PCR-adjusted adequate clinical and parasitological response,
estimated by Kaplan Meier survival and Per Protocol analysis, was extremely high for both drugs (99.6% for mefloquine-
artesunate and 98.4% and for dihydroartemisinin-piperaquine) (RR: 0.99, 95%CI [0.9721.01], Fisher Exact p= 0.21). All
recrudescences were late parasitological failures. Overall, gametocytes were cleared faster in the mefloquine-artesunate group
(28 vs 35 days) and new gametocytes tended to appear more frequently in patients treated with dihydroartemisinin-
piperaquine (day 7: 8 (3.6%) vs 2 (0.9%), RR: 3.84, 95%CI [0.82–17.87]). Adverse events such as anxiety and insomnia were
significantly more frequent in the mefloquine-artesunate group, both in adults and children. Conclusion. Dihydroartemisinin-
piperaquine is as effective as mefloquine-artesunate in treating uncomplicated P. falciparum malaria but it is better tolerated
and more affordable than mefloquine-artesunate (US$1.0 versus US$18.65 on the local market). Therefore, it should be
considered as a potential candidate for the first line treatment of P.falciparum malaria in Peru. Trial Registration.
ClinicalTrials.gov NCT00373607 [http://www.clinicaltrials.gov/ct/show/NCT00373607]
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INTRODUCTION
In Peru, malaria is one of the most common parasitic diseases and
an important public health problem. The highest incidence of P.
falciparum malaria occurs in the Peruvian Amazon region where
the current first line treatment, mefloquine associated with
artesunate (MAS3), was introduced in 2001 following high
resistance to chloroquine (CQ) and sulfadoxine/pyrimethamine
(SP) [1–2]. Though highly efficacious against multi-drug resistant
P. falciparum, MAS3 is not well tolerated and its compliance is poor:
14% of treated patients experienced adverse events in a post-
marketing surveillance study carried out in Peru [3]. In addition,
MAS3 is extremely expensive for the Peruvian Ministry of Health
which fully subsidises its costs at 18.65 USD per adult treatment
[4].
Dihydroartemisinin-piperaquine (DHA-PPQ) is a new artemi-
sinin-containing fixed-combination treatment (ACT) that has
proved to be well tolerated and highly efficacious against
uncomplicated P. falciparum malaria in Southeast Asia [5–11]
and in Africa [12]. Piperaquine, an orally active bisquinoline, is
structurally related to CQ. Piperaquine and aminoquinolines such
as CQ may have similar targets, possibly the inhibition of the
heme-digestion pathway in the parasite food vacuole [13]. Some
resistance did develop in China when piperaquine was widely used
as monotherapy against CQ-resistant P. falciparum. However, its
combination with dihydroartemisinin has shown to be active
against multi-drug resistant P. falciparum [8]. DHA-PPQ is not only
much cheaper than MAS3 (1.00 USD versus 18.65 USD per adult
treatment) [4] but it is also co-formulated, a major advantage
favouring higher patient’s compliance. DHA-PPQ has been
registered in China, Cambodia and recently in Vietnam, where
it represents a substantial percentage of the national consumption
of anti-malarial treatments [14].
We have carried out the first clinical trial in Latin America
evaluating the safety, tolerability and efficacy of DHA-PPQ vs the
current MAS3 regimen in Peruvian patients with uncomplicated
P. falciparum malaria and results are reported below.
MATERIALS AND METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
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Study design, sites and patient treatments
A randomised, open-label clinical trial was carried out between
July 2003 and July 2005 in 9 health posts (HP) and 4 commune
health centres (CHC) in the rural communities located south of
Iquitos, the largest city in the Peruvian Amazon region (population
approximately 350,000 inhabitants) [15]. All health facilities draw
their patients from the rural areas surrounding the town. Malaria
transmission in the area is low with a peak between November and
June; the main vector is Anopheles darlingi [16]. Plasmodium falciparum
represents 20%–30% of all malaria infections, the rest being due to
P. vivax. All age groups are at risk, with the majority of infections
progressing towards symptomatic disease, though severe malaria
cases are rare [17].
Patients aged 5–60 years old attending the health facilities and
with suspected clinical malaria had a blood slide done (thick blood
film). If positive for P. falciparum they were referred to the San Juan
Health Centre where another blood slide was collected. They were
enrolled in the study if they met, besides being in the required age
range, the following inclusion criteria: fever (axillary tempera-
ture$37.5uC) or history of fever in the preceding 24 h and mono-
infection with P. falciparum with asexual parasite density between
1,000 and 200,000/ml. Patients were excluded if they had at least
one of the following exclusion criteria: severe malaria, pregnancy
or lactation, any other concomitant illness or underlying disease,
contra-indication to the trial drugs, history of treatment with
mefloquine in the last 60 days or CQ, primaquine or quinine
within the 14 days before the current episode.
Patients meeting the inclusion/exclusion criteria were enrolled
in the study only after written informed consent was obtained from
them or their carer. The study protocol was approved by the
Ethical Review Committee of the Universidad Peruana Cayetano
Heredia and that of the Institute of Tropical Medicine, Antwerp,
Belgium. The research was performed in accordance with the
ethical standards of the Peruvian Ministry of Health. The trial has
been registered as an International Standard Randomised
Controlled Trial, number NCT00373607 at http://www.
clinicaltrials.gov.
Patients were randomised in blocks of ten to receive either
MAS3 or DHA-PPQ. Sealed opaque envelops containing the
treatment allocations were opened only after the final decision to
recruit the patient had been made. Drugs were administered once
daily for 3 days according to the patient’s body weight:
MQ = 8 mg/kg/day (LariamTM, Hoffman-La Roche Co., Basel,
Switzerland) and AS = 4 mg/kg/day (ArtesunateTM, Guilin Phar-
maceutical Factory, Guilin, China), DHA-PPQ = 2.1 mg/kg/day
DHA and 16.8 mg/kg/day PPQ (ArtekinTM; Holleykin pharma-
ceuticals, Guangzhou, China). The number of pills was rounded
off to the nearest quarter tablet. Patients were observed for 1 hour:
if vomiting occurred within 30 min of dosing, a full dose was re-
administered; if vomiting occurred between 30 min and 1 hour
only half dose was re-administered. For young children, drugs
were crushed, dissolved in water and squirted into their mouths.
Treatment follow-up
All enrolled patients were followed up daily until day 3 (24–48–
72 h) and were asked to return on days 7, 14, 21, 28, 35, 42, 49, 56
and 63 or outside scheduled visits if any symptom occurred. If the
patient did not report for scheduled visits, every effort was made to
locate him/her at the home address. During each visit, a clinical
assessment was done and a blood sample for parasitaemia taken by
finger prick. At Day 0 and at any visit from Day 7 onwards, a blood
spot on filter paper was also taken for later PCR analysis on
recurrent parasitemia cases. PCV was measured at Day 0, 7 and
14; for those still in the follow up, a last measurement was done at
day 63; anaemia was defined as a PCV#33%. A venous blood
sample was taken at D0 and D7 for a complete blood count, liver
and renal function tests. Rescue treatment was provided to
patients with recurrent parasitaemia or with serious adverse events
requiring treatment withdrawal. Patients treated with DHA-PPQ
were given MAS3 and those on MAS3 received DHA-PPQ.
Severe malaria cases were treated with parenteral quinine. P.vivax
infections were treated with chloroquine (25 mg/kg over 3 days).
Clinical and laboratory procedures
Clinical examination systematically assessed body temperature
(axillary temperature), heart and respiratory rate, blood pressure,
liver and spleen size. All signs and symptoms were systematically
recorded on a pre-coded standardized form.
The thick and thin blood films were stained with Giemsa 10%
for 10 minutes and reading for species determination and parasite
density was blinded to treatment. Parasite density was calculated
by counting the number of asexual forms for 200 white blood cells
(WBC) and assuming 8,000 WBC/ml. A blood smear was declared
negative if no asexual form was detected after reading 100
microscopic fields. If sexual forms were detected, a gametocyte
count was performed against 1,000 WBC. Quality control was
performed on 10% of all slides (random sample) at the National
Hospital of the Cayetano Heredia University in Lima. The
agreement between the first and second reading was 98%.
PCV was measured using micro capillary tubes which were
centrifuged and PCV determined following the Hawksley micro-
haematocrit reading method [18].
A blood spot (2 cm2) was taken on filter paper (Whatman nu3)
for later PCR analysis. Each PCR filter paper was dried and stored
individually in a plastic bag containing silica gel. Parasite
genotyping was done by a nested PCR for variable blocks within
the merozoite surface protein 1 (MSP1), MSP2 and glutamate-rich
protein (GLURP), as described previously [19–21]. A recrudescent
infection was defined as one that showed match in size of at least
one allele for all 3 genes (MSP1, MSP2 and GLURP) between Day
0 and the day of recurrent parasitemia. A new infection was
defined when a different genotyping pattern was observed in at
least one of the 3 genes, between Day 0 and the day of recurrent
parasitemia. When it was not possible to distinguish recrudescence
from new infection, the sample was classified as indeterminate.
Sample size calculation
Assuming a risk of recrudescence adjusted by genotyping of 6% for
MAS3 and 1% for DHA-PPQ group, we calculated that
a minimum of 250 patients would be needed in each treatment
arm to detect a significant difference at 5% significance level and
80% power.
Study end-points and case definitions
The primary outcome was the PCR-corrected cure rate at day 63.
Secondary outcomes were parasite clearance and fever clearance,
gametocyte carriage and incidence of adverse events (AE).
Treatment outcome was established according to the World
Health Organization and Pan American Health Organization
guidelines for in vivo drug testing [22]. Early treatment failure
(ETF) was defined as one of the following: (i) danger signs or severe
malaria at Days 1, 2 or 3 with parasitaemia; (ii) parasite density at
Day 2.Day 0; (iii) parasitaemia at Day 3 with fever (axillary
temperature$37.5uC); (iv) parasitemia at Day 3$25% than Day
0. Late clinical failure (LCF) was defined as danger signs, severe
malaria or parasitaemia and fever between Days 4 and 63 without
Dihydroartemisin-Piperaquine
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having been previously classified as ETF. Late parasitological
failure (LPF) was defined as recurrent parasitaemia between Day 4
and 63 without fever and without previously meeting any of the
criteria for ETF or LCF. Adequate Clinical and Parasitological
Response (ACPR) was defined as no parasitaemia until Day 63
without previously meeting any of the criteria for ETF, LCF, and
LPF.
An adverse event (AE) was defined as ‘‘any unfavourable and
unintended sign, symptom, or disease temporally associated with
the use of the drug administered’’.
Statistical analysis
Data were double-entered and cleaned in ACCESS, Microsoft
office 2003, and analysed in STATA version 8.0 (Stata
Corporation, College Station, Texas, US). Descriptive statistics
were used to summarise baseline clinical and biological values of
all randomized patients. All PCR indeterminate results were
considered as treatment failures, adopting a worst case scenario.
Data were analysed by Intention-to-treat (ITT), Per-protocol
(PP) and Kaplan Meier survival analysis to determine the cure rate
(PCR-adjusted) at day 63 in each treatment group. In the ITT
analysis, patients lost to follow up were considered as treatment
failures (worst case scenario) and the denominators constituted by
the patients initially randomized to each group. In the PP analysis,
patients lost to follow-up and those excluded after enrolment were
excluded from the analysis, and only patients with complete
follow-up were included in the denominator. In the ITT and PP
analysis, cure rates were compared using chi-square (x2) test with
Yates’ correction or two-tailed Fisher’s exact test as appropriate. In
the Kaplan Meier survival analysis, each patient contributed to the
analysis for the time s/he was followed up. Patients lost to follow
up or with a new Plasmodium infection (P.falciparum, P.vivax) were
censored at the time they were last seen for the primary outcome.
In the survival analysis, cure rates were described by Kaplan
Meier estimates and compared between groups with a log-rank
test. Gametocyte carriage rates were estimated as proportion of
patients with gametocytemia at day 0, 7, 14, etc, until total
clearance in both groups, and person-gametocyte-weeks were
calculated to measure gametocyte carriage and transmission
potential. The person-gametocyte-weeks rates were calculated as
the number of weeks in which blood slides were positive for
gametocytes during the 2 first weeks of follow-up after treatment
divided by the number of all follow-up weeks and expressed per
1,000 person-weeks. The risk of adverse events during the first
week after the start of the treatment was calculated for each group
separately in children and adults. Relative risks and p-values were
computed using chi-square (x2) test with Yates’ correction or two-
tailed Fisher’s exact test as appropriate.
RESULTS
Patient’s characteristics
Out of 961 patients screened at the San Juan Health Centre where
all potential study subjects were referred from the surrounding
health facilities, 522 were enrolled in the study, 262 randomized to
DHA-PPQ and 260 to MAS3 (Figure 1). The main reasons for
ineligibility were low parasitemia (85%) and unwillingness to
participate because not available for the whole follow-up period
(11%). Two third of the patients (65%) were adults (18–60 years
old) and the rest children 5–17 year old. Twenty two (8%) patients
treated with DHA-PPQ and 15 (6%) with MAS3 were lost to
follow up, the main reason being having left the study area because
of work (forest workers, etc). These patients were included in the
survival analysis as event-free for the time they participated, while
in the ITT analysis they were considered as failures, and in the PP
they were excluded from the analysis. Baseline characteristics were
comparable in the 2 groups, except for gametocytaemia on
admission which was slightly higher in MAS3 (17%) than in the
DHA-PPQ (13%) group (p = 0.31). The median PCV at day 0 was
comparable in both treatment groups (Table 1). No difference was
detected at day 7 (36% for DHA-PPQ and 35% for MAS3) and
day 14 (35% in both groups). At day 63, median PCV was 38% in
both groups, a similar value than that at day 0. The prevalence of
anaemia was 24% for the DHA-PPQ and 20% for the MAS3
group at day 0, 30% in both groups at day 14 and 15% for DHA-
PPQ and 10%, for MAS3 at day 63.
No patient had abnormal liver and renal function test results of
clinical significance, both at entry and at day 7 (data not shown).
Clinical and parasitological outcomes
Twenty-four hours after the first dose, a significantly higher
proportion of patients in the DHA-PPQ group had cleared
parasitaemia [67.7% versus 58.5%, p = 0.03], though this difference
tended to disappear at day 2 so that by day 3 all patients had
cleared parasitaemia (Table 2). Fever clearance was equally high,
at day 2 almost all patients were afebrile, with no difference
between the 2 groups (Table 2).
No ETF was observed. Between Day 4 and 63, 23 patients
(10%) in the DHA-PPQ and 12 (5%) in MAS3 group had
recurrent parasitemia, among which P. vivax represented 11 and
10 infections, respectively (Table 2). In the DHA-PPQ group and
after PCR genotyping, 8 of the 12 recurrent falciparum infections
were classified as new infection and 4 as recrudescence (at day 13,
25, 42, and 63). In the MAS3 group, there was one new infection
and 1 with indeterminate PCR result that was classified as
recrudescence (at day 37). All recrudescences were classified as
LPF.
The PCR-corrected ACPR obtained by survival analysis was
98.4% [95% CI: 96.7–99.4] in the DHA-PPQ group and 99.6%
[95% CI: 97.2–99.9] in the MAS3 group (log rank p = 0.18).
Results were very similar in the PP analysis, 98.3% vs 99.6% (RR:
0.99, 95%CI [0.9721.01], Fisher Exact p = 0.21). In the ITT
analysis, the ACPR was obviously lower than the other estimates,
90.1% [95%CI: 85.8–93.4] for DHA-PPQ and 93.8% [95%CI:
90.2–96.4] for MAS3, but not significantly different (RR: 0.98,
95%CI [0.8621.11], x2 p = 0.79].
Before treatment, 35 patients (13%) in DHA-PPQ and 43
patients (17%) in the MAS3 group had gametocytaemia. After
treatment, the gametocyte carriage rate decreased faster in MAS3
(gametocytes cleared by day 28) than in the DHA-PPQ group
(gametocytes cleared by day 35) (Figure 2). Among patients with
gametocytes at day 0, gametocyte clearance at day 7 was similar in
the 2 treatment groups (73.5%, 25/34 for DHA-PPQ and 84.0%,
36/43 for MAS3; p = 0.27) while it was significantly different at
day 14 (73.5%, 25/34 for DHA-PPQ and 98.0%, 41/42 for
MAS3; p = 0.002). Among patients without gametocytes at day 0,
8 (3.6%) in the DHA-PPQ group and 2 (0.9%) in the MAS3 group
had gametocytes in at least one blood slide between day 0 and 7
(RR: 3.84, 95%CI [0.82–17.87]); no new cases of gametocytaemia
were detected between day 7 and day 14. Gametocyte carriage
measured as person-gametocyte-weeks was higher but not
significantly different in the DHA-PPQ (32.5/1000) than in
MAS3 group (24.9/1000) (p = 0.31) (Table 3).
Adverse events
Overall during the first week of treatment, adverse events were
more frequent among patients treated with MAS3 compared to
Dihydroartemisin-Piperaquine
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1101
those treated with DHA-PPQ (Table 4), and they were also more
severe in the former group (data not shown). In adults as well as in
children, dizziness and nausea were the most common reported
adverse events. In adults treated with DHA-PPQ, dizziness,
nausea and vomiting were significantly less frequent than in those
treated with MAS3. Similarly, although insomnia and anxiety
were less frequent, they occurred significantly less often in adults
treated with DHA-PPQ (p,0.001). Somnolence was rare and not
observed in the MAS3 group. Among children, the higher
frequency of adverse events in the MAS3 group was significant
only for insomnia and anxiety. Vomiting within one hour of
treatment intake occurred rarely and with the same frequency in
both groups (4%: 10 patients in the DHA-PPQ and 11 in the
MAS3 group).
The majority of adverse events were transient and resolved
spontaneously with the only exception of a woman who
Figure 1. Trial profile.
doi:10.1371/journal.pone.0001101.g001
Table 1. Baseline characteristics of all randomized patients by treatment group.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CHARACTERISTICS DHA-PPQ MAS3
Number of patients 262 260
Sex ratio (Male/Female) 1.4 (152/110) 1.6 (161/99)
Age groups (years)
5–17 94 (36%) 91 (35%)
.17 168 (64%) 169 (65%)
Body weight (Kg), median [Q1–Q3] 52.5 [38.8–60.2] 51.9 [39.8–59.4]
Geometric mean parasite count/mL [95%CI] 5,866 [5,214; 6,600] 5,304 [4,731; 5,946]
Gametocytaemia on admission 35 (13%) 43 (17%)
Axillary temperature$37.5uC 137 (52%) 126 (48%)
Haemoglobin (g/dl), mean6SD 12.261.7 12.261.6
PCV (%), median [Q1–Q3]u 38 [34–41] 37 [34–40]
u[Q1–Q3] = inter-quartile range = [Lower–Upper Quartile].
doi:10.1371/journal.pone.0001101.t001..
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complained of anxiety and insomnia during the whole follow-up
period and needed the administration of sedatives and anxiolytic
drugs. Serious drug-related adverse events requiring early
treatment termination occurred in 3 patients treated with
MAS3. A 30 years old man suddenly presented at day 4 with
severe dizziness, loss of balance, unsteadiness, amnesia and severe
anxiety. Immediately after the end of the treatment, he reported
severe headache and insomnia. Clinical and biological examina-
tions diagnosed a toxic metabolic encephalopathy, possibly due to
MAS3. A 41 years old man had severe weakness, anxiety, and
transient arrhythmia 30 minutes after the second dose of MAS3.
The third patient, a 6 years old boy, presented with palpitations
and chest pain, 12 hours after the second dose of MAS3.
DISCUSSION
This first clinical trial carried out in South America on DHA-PPQ
showed that this new fixed-dose ACT is as efficacious as MAS3
but better tolerated and with significantly less adverse events.
These excellent results strongly support DHA-PPQ as a good
alternative to MAS3, the current first line treatment in the
Peruvian Amazon region. Moreover, compared to MAS3, DHA-
PPQ is less expensive (1.00 USD versus 18.65 USD per adult
treatment) [4], a major advantage for the Peruvian health
authorities that fully subsidise antimalarial treatment. Cure rates
at the end of the follow up were extremely high for both treatment
groups, regardless of the analysis method, though MAS3 tended to
have higher cure rates. Our results are conservative, since we
opted for the worst case scenario and considered indeterminate
PCR results as recrudescence. In the best case scenario, the 63 day
cure rate would have been 100% in the MAS3 group. Our results
are similar to those reported for DHA-PPQ from Southeast Asia:
Thailand (63-day cure rate 96.1% [7]), Burma (42-day cure rate
99.4% [10]), Cambodia (28-day cure rate 96.9% [6], 63-day cure
rate 97.5% [11]), Vietnam (56-day cure rate 98.7% [8]); and from
a recent study in Rwanda (28-day cure rate 95.2% [12]).
Most patients lost to follow up were forest workers who had to
go and work outside the study area. It is impossible to know
whether they experienced a recurrent infection within the 63 days
Table 2. Clinical and parasitological outcomes by treatment group.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RESULTS DHA-PPQ MAS3 p-value
Parasite clearance at 24 hours 67.7% (176/260) 58.5% (152/260) 0.03
‘‘ ‘‘ at 48 hours 98.9% (257/260) 96.2% (250/260) 0.05
Fever clearance at 24 hours 88.9% (232/261) 88.1% (229/260) 0.77
‘‘ ‘‘ at 48 hours 98.5% (255/259) 99.6% (259/260) 0.18
ETF 0 0
Total recurrent parasitemia day 4–63 10% (23/230) 5% (12/236) 0.07
- P.vivax infections 11 10 0.07
- New P.falciparum infections 8 1
- Late Parasitological Failure-PCR corrected 4 1*
63-day cure rate (ACPR-PCR adjusted)
- Intention-to-treat 90.1% (236/262) 93.8% (244/260) 0.15
- Per protocol 98.3% (226/230) 99.6% (235/236) 0.21
- Kaplan-Meier survival analysis 98.4% 99.6% 0.18u
ETF= Early Treatment Failure; ACPR=Adequate Clinical and Parasitological Failure; * PCR indeterminate classified recrudescence;u Logrank test.
doi:10.1371/journal.pone.0001101.t002..
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Figure 2. Proportions of patients with gametocytemia during the follow up.
doi:10.1371/journal.pone.0001101.g002
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after treatment but it is unlikely that all of them had a re-
crudescence. However, all of them were considered as failures in
that ITT analysis, usually recommended in superiority trials to
avoid potential bias introduced by patients lost to follow-up [23].
This is why the ACPR computed by ITT analysis is likely to be an
underestimation of the true cure rate.
Though patients in the MAS3 group had a slightly higher
prevalence of gametocytemia before treatment, they cleared it
more rapidly than patients in the DHA-PPQ group. The latter had
a higher person-gametocyte-weeks rate but the difference was not
significant compared to MAS3. New gametocytes appeared more
frequently during the first week in patients treated with DHA-PPQ
than those treated with MAS3, but these small differences were
not found significant with the power of our study. As mentioned
previously, the lower dose of artemisinin contained in DHA-PPQ
as compared to MAS3 may be responsible of these differences
[7,10].
The incidence of new infections was higher in the DHA-PPQ
than in the MAS3 group, possibly reflecting the shorter post-
treatment prophylactic effect of piperaquine as compared with
mefloquine. It should be noted that all new infections in the DHA-
PPQ group occurred at least one month after treatment, from day
35 onwards (most of them, six out of 8, by day 49 or later), while in
the MAS3 group the only new infection detected occurred at day
21. However, a similar study (63-day follow up) carried out in
Cambodia in a low transmission area and comparing DHA-PPQ
with MAS3 did not report any difference in the incidence of new
infections [11].
The occurrence of adverse events was generally lower and less
severe in patients treated with DHA-PPQ than in those treated
with MAS3, both in adults and children. Their high occurrence in
the MAS3 group differ considerably from that observed in another
trial carried out in Peru in 2000 [24], in which very few cases of
vomiting and insomnia were reported, possibly because of the
lower dose of MQ (15 mg/kg) administered. Since our study was
not blinded, responder bias cannot be ruled out: patients in the
MAS3 group, especially adults, were more likely to report adverse
events (especially gastro-intestinal) since some of them may have
had previous negative experiences with this antimalarial treat-
ment. Nevertheless, most adverse events observed in our patients
are known to occur with MAS3 and their frequency was similar to
that reported in previous trials [8–11]. Neuro-psychiatric events,
such as anxiety and insomnia, were much less frequent in the
DHA-PPQ group, and the difference was significant both in
adults and children. It is difficult to say whether this is a true
difference or due to a responder bias, both for adults and for
the children’s parents/caretakers. Nevertheless, the type and
frequency of adverse events reported is consistent in both age
groups and indicate a lower tolerability of MAS3 as compared to
DHA-PPQ.
Table 3. Gametocyte prevalence and incidence by treatment group.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DHA-PPQ MAS3 p-value
Gametocyte prevalence
Day 0 35/262 (13.4%) 43/260 (16.5%) 0.31
Day 7 17/256 (6.6%) 9/256 (3.5%) 0.11
Day 14 10/253 (4.0%) 1/253 (0.4%) 0.006
Day 21 1/247 (0.4%) 1/250 (0.4%) 0.99
Day 28 3/243 (1.2%) 0/249 0.08
Day 35 0/243 0/245
Gametocytes incidence
Day 7 8/222 (3.6%) 2/213 (0.9%) 0.06
Day 14 0/209 0/208
Person-gametocyte-weeks (/1000 person-weeks) 32.5 (71/2182) 24.9 (55/2207) 0.31
doi:10.1371/journal.pone.0001101.t003..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Table 4. Adverse events by age and treatment group within the first week of follow up.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ADULTS CHILDREN
DHA-PPQ MAS3 Relative Risk p DHA-PPQ MAS3 Relative Risk p-value
Nausea 77/161 (48%) 100/164 (61%) 0.78 0.02 49/101 (49%) 56/96 (58%) 0.83 0.17
Vomiting 29/161 (18%) 48/164 (29%) 0.62 0.02 24/101 (24%) 25/96 (26%) 0.91 0.71
Dizziness 122/161 (76%) 152/164 (93%) 0.82 ,0.001 63/101 (62%) 66/96 (69%) 0.91 0.35
Anorexia 69/161 (43%) 77/164 (47%) 0.91 0.46 42/101 (42%) 35/96 (36%) 1.14 0.46
Abdominal pain 42/161(26%) 45/164(27%) 0.95 0.78 31/101 (31%) 34/96 (35%) 0.87 0.48
Insomnia 22/161 (14%) 71/164 (43%) 0.32 ,0.001 5/101 (0.5%) 27/96 (28%) 0.18 ,0.001
Somnolence 5/161 (3%) 0/164 . 0.02 3/101 (2.3%) 0/96 . 0.09
Anxiety 3/161 (1.2%) 24 (15%) 0.13 ,0.001 0/101 5/96 (5%) 0 0.02
doi:10.1371/journal.pone.0001101.t004..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
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In conclusion, our study confirmed that DHA-PPQ is a highly
effective antimalarial treatment for P. falciparum malaria in the
Amazon region of Peru. This co-formulation is safe and better
tolerated than MAS3 and thus may have a better compliance. All
these advantages combined to its low cost makes DHA-PPQ
a suitable and even advisable first line treatment for P. falciparum
malaria in Peru. Our encouraging results should prompt
neighbouring endemic countries to conduct similar efficacy trials,
and possibly change their anti-malaria treatment policy to this
highly efficacious, safe, well tolerated and affordable ACT.
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